

04

July • August
2025

EuroLab News

THE EFLM BI-MONTHLY NEWSLETTER

**NEWS FROM THE LAST
EFLM EXECUTIVE BOARD MEETING**

NEWS

**Read how EFLM is driving
excellence in Lab Practice**

www.eflm.eu

Editorial Information

Newsletter Editor: Dr. Harjit Pal Bhattoa, Faculty of Medicine,
Dep of Laboratory Medicine, University of Debrecen Hungary

EFLM Executive Board:

M. Plebani, T. Ozben, T. Zima, S. Jovicic, K. Kohse,
P. Fernandez-Calle, D. Vitkus

To send your news or advertisement for publication on the newsletter write to: news@eflm.eu Contents may not be reproduced without the prior permission of the newsletter Editor. The EFLM Newsletter is published bi-monthly.

Foreword

Perhaps this refreshing issue of the EuroLabNews will help beat the summer heat! Mario Plebani, EFLM President, presents the latest updates from the last Executive Board Meeting held in Madrid. Snezana Jovicic, EFLM Executive Board Secretary, announces the EFLM Walter Guder Preanalytical Award. Pilar Fernandez-Calle, EFLM Executive Board Member-at-large and Joe Lennerz, Chair of the EFLM Committee on Integrative Diagnostics, summarize the EFLM Symposium "Integrated Diagnostics – Interdisciplinary Strategies and Approaches" held in Brussels during the EuroMedLab Congress 2025. Our heartiest congratulations to our President, Professor Mario Plebani for his 1 ranking among highly cited scholars. Alessia Carere, EFLM Office, announces the latest vacancies in EFLM Committees. She also reports the Changing of the Guard in the UK and Danish societies. Irem Açılan from Türkiye share her EFLMLab X training experience as the latest EFLM bursary recipient. Luisa Agnello, Member of the EFLM Committee on Harmonisation calls for participation in the EFLM Survey on Alzheimer's Disease Biomarkers. Tomris Ozben, Chair of the EFLM Committee "Green & Sustainable Laboratories" shares 4 simple actions to be more sustainable and green in our laboratory. Official translations of this initiative are also available on the EFLM website. Alessia Carere, EFLM Office, provides a list of the latest EFLM publications. Aleš Kvasnička, Chair of the Committee: Young Scientists and Member of the Committee: Promotion & Publications, reports on 4 EFLM webinars held in the recent past and creates an appetite for the upcoming ones. Happenings at the Serbian, Spanish, French and Belgian Societies are reported by their respective representatives. Neda Milinković and Snežana Jovičić present the highlights of the EFLM Postgraduate Course on Biostatistics in Laboratory Medicine – held in collaboration with the Society of Medical Biochemists of Serbia. The IFCC corner summarizes the global happenings in the Laboratory profession. As a help to plan in due time, major upcoming EFLM Events are also listed.



Reported by **Harjit Pal Bhattoa**,
Editor EFLM EuroLabNews

Contents

Foreword

1

Updates from the last EFLM Executive Board Meeting

2

The EFLM Executive Board informs

3

EFLM office informs

6

Changing of the Guard in EFLM National Societies

7

News from the EFLM Functional Units

8

EFLMLabX Corner

9

Updates on EFLM publications

12

Past EFLM Events

13

Upcoming EFLM Events

14

News from EFLM National Societies

18

News from Events Under EFLM Auspices

22

IFCC News

23

Calendar of EFLM events and events under EFLM auspices

24

Highlights



**NEWS FROM THE
EFLM PRESIDENT**



**EFLM SYMPOSIUM
ON INTEGRATED
DIAGNOSTICS**



EFLM AWARD

From the EFLM President

Updates from the last Executive Board Meeting

by Mario Plebani, EFLM President



Dear Colleagues,

I am pleased to share with you some important updates following the meeting of the EFLM Executive Board, recently held in Madrid and hosted by the Spanish Society of Laboratory Medicine (SEMEDLAB).

As first point, the Executive Board reviewed the outcomes of the **EuroMedLab 2025 Congress**, held this past May, and exchanged immediate feedback to guide improvements for future editions. The aim is to ensure that the EuroMedLab experience continues to evolve in line with the expectations and the needs of the laboratory medicine community.

Moreover, several proposals from the Executive Committee of EFLM Division "Science: Value Based Laboratory Medicine" (D-S) were discussed. Among them, the Executive Board warmly welcomed the idea of launching a one-day **"EFLM Meeting of Science, Quality and Value of Laboratory Medicine"**, to be held every two years, preferably in conjunction with the EFLM Preanalytical Conference. This initiative is intended to enhance synergies across EFLM projects and to foster scientific and professional collaboration.

Another key decision was the establishment of a new EFLM Functional Unit on "Laboratory Error Database", inspired by an idea from Hikmet Can Cubucku: a database designed to assist clinical laboratory professionals and clinicians in identifying potential laboratory errors and suggesting actions to avoid or reduce possible patients' harm. In today's landscape of rapidly evolving diagnostics, the importance of accurate laboratory measurements cannot be overstated. This new resource represents a step toward a more standardized and transparent approach to documenting laboratory errors - but its success depends on our collective commitment and contribution.

This project further demonstrates EFLM's leadership in developing tools that support laboratory practice, following the path of other successful EFLM initiatives such as:

- the **EFLM Biological Variation Database**, a critical appraisal tool for evaluating BV studies, based on systematic reviews of existing literature.
- the **EFLM APS Calculator**, a data-driven tool for defining outcome-based analytical performance specifications for measurement uncertainty, using specific clinical needs and population data.

Last but not least, I am delighted to announce the appointment of **Dr. Ruben Smeets** as Chair of the newly established **EFLM Committee on Exchange of Laboratory Data (C-ExLD)**. Dr. Smeets is a clinical chemist and Medical Information Officer for diagnostics at Radboud University Medical Centre. With extensive experience in diagnostic data coding, he collaborates with both EFLM C-PRE and C-POST to develop codes for pre-analytical errors. He also contributes to HL7 working groups in the Netherlands and across Europe and has successfully developed European-level coding systems for pre-analytical non-conformities. Dr. Smeets is an excellent choice to contribute to the implementation of the EU Health Data Space and facilitate data exchange at the European level and we warmly welcome him in the EFLM Community.

Finally, after the meeting in Brussels with the board of MedTech Europe, I would like to inform you that we decided to improve the cooperation focusing on some issues already reported in the MoU signed last year, including efforts to improve the new IVDR, projects to promote sustainability and value of laboratory medicine.

As we now step into the summer season, I would like to take this opportunity to wish you all a restful and enjoyable break. May it be a time to recharge, reconnect, and return with renewed energy and inspiration. I also extend my warmest wishes for a smooth and successful restart in the coming months, as we continue working together to advance laboratory medicine across Europe.


Mario Plebani
EFLM President

THE EFLM EXECUTIVE BOARD INFORMS

EFLM Walter Guder Preanalytical Award

Reported by **Snezana Jovicic**, EFLM Executive Board Secretary

The EFLM Executive Board is pleased to announce the EFLM Walter Guder Preanalytical Award, which has been restored after several years, thanks to the support of BD.



The EFLM Walter Guder Preanalytical Award is granted to the best published paper, as judged by an independent panel of experts, demonstrating an important and novel contribution to the advancement of the preanalytical phase. EFLM is very pleased to have partnered with BD on this award, through which we intend to achieve wider recognition of the importance of high-quality research in the field of preanalytical phase among laboratory professionals in Europe. The Award, consisting of a sum of 5,000 Euro in addition to the coverage of the conference registration and travel/accommodation expenses, will be presented to the winner at the **7th EFLM Conference on Preanalytical Phase in Padova (IT) on 12-13 December 2025**. The Award will be presented to the First Author, who is responsible for the division of the award among his/her co-authors.

Applications must be submitted by the first author of the paper and must be accompanied by:

- Reprint of the publication or (in case of publications in press), a manuscript copy and a copy of the journal Editor's letter indicating the final acceptance for publication.
- A short bio sketch of the submitting author.
- Document proving the membership to an EFLM Full Member National Society/Association.
- Copy of the ID proving the age of the applicant.
- Statement signed by all authors of the publication consenting to submission of the paper for the Award and to the conditions of entry.

[CLICK HERE TO DOWNLOAD THE LEAFLET](#)

Applications should be submitted via e-mail
to EFLM at eflm@eflm.eu by 30 September 2025

Entry criteria

- the submitting author must be a young scientist less than 40 years of age as of 1st January 2025, First Author of the paper and from a National Society/Association Full Member of EFLM. The applicant is limited to one submission only;
- entries must be published studies demonstrating an important and novel contribution to the advancement of the preanalytical phase. Only original research articles are eligible. Reviews, opinion papers, or papers out of the scope of the Award will not be accepted for evaluation;
- entries must have been published or finally accepted for publication between the year of the award and the previous full calendar year and must be published in English in a peer-reviewed medical, scientific or health economics journal;
- all authors of the publication have to agree on the submission of the paper for the Award and to the conditions of entry; the applicant must not have applied or be nominated for any other on-going EFLM or IFCC Awards and neither must result as the winner of those Awards in the same year when the award is presented.

Walter Guder: a pioneer of the preanalytical phase in Laboratory Medicine



The name Walter Guder (Emeritus Professor of the Ludwig-Maximilian-University of Munich) is inextricably linked to the modern understanding and recognition of the pre-analytical phase in laboratory diagnostics. In his honour, EFLM has established an Award dedicated to this critical area, acknowledging his pioneering role and forward-looking vision that transformed the way diagnostic processes are managed today.

In the 1970s, Guder was among the first to introduce the term “preanalytical phase” in the scientific literature, defining it as all the activities and variables that occur before the analytical process, within what he described as the “brain-to-brain loop” of medical diagnostics. His attention focused on all those factors that, while preceding the actual analysis, critically affect its reliability — from proper sample collection and patient identification to transport and storage of biological materials.

His book “Pre-Examination Procedures in Laboratory Diagnostics: Preanalytical Aspects and their impact on the Quality of Medical Laboratory Results”, published in 2015, has inspired the work of many laboratory professionals and the awareness on the need to improve all steps of the preanalytical phase.

The EFLM Walter Guder Award not only honours a great scientist, but also an educator and innovator who brought to light a previously overlooked yet essential part of the diagnostic process. His legacy continues to inspire new generations of laboratory medicine professionals around the world.

EFLM SYMPOSIUM "Integrated Diagnostics – Interdisciplinary Strategies and Approaches" EuroMedLab Congress 2025, Brussels

Reported by **Pilar Fernandez-Calle**, EFLM Executive Board Member-at-large and **Joe Lennerz**, Chair of the EFLM Committee on Integrative Diagnostics

The EFLM Symposium "Integrated Diagnostics – Interdisciplinary Strategies and Approaches" held in Brussels during the EuroMedLab Congress 2025 represented a historic event in the collaboration between EFLM and the European Society of Radiology (ESR). It marked a memorable and tangible step forward in fulfilling Article 2 of the memorandum of understanding (MOU), which affirms: "ESR and EFLM agree to organise joint sessions at each other's congresses upon consultation with the respective Programme Planning Committee Chairs. These joint sessions should preferably be integrated into the scientific programme."

The symposium delivered a scientific programme, highlighting the importance and impact of integrated diagnostics across disciplines. Pieter Vermeersch (Belgium) provided an excellent overview of the European Health Data Space (EHDS); Regina Beets-Tan (the Netherlands) outlined numerous critical considerations from the radiology perspective. Norman Zerbe (Germany) clearly resonated on interoperability and Katrin Frauenknecht (Luxembourg) offered a deep insight into integrative approaches within neuropathology. The high level of engagement was reflected in the number of attendees, as well as the high number and depth of questions during the panel discussion.

Special thanks are due to Pilar Fernandez-Calle (Spain), Joe Lennerz (Germany/USA) and Michel Langlois (Belgium) for their invaluable contributions to the moderation and behind-the-scenes organization, and for driving this initiative forward at the executive level.



Joe Lennerz (Germany/USA), Regina Beets-Tan (NL), Pilar Fernandez-Calle (Spain), Norman Zerbe (Germany), Katrin Frauenknecht (Luxembourg), Peter Vermeersch (Belgium)

This symposium not only fulfilled a formal agreement; it laid the groundwork for a new era of collaboration between Laboratory Medicine and Radiology, with the shared goal of advancing patient care through integration. Importantly, integrated diagnostics must evolve beyond radiology to encompass all diagnostic disciplines – Anatomic Pathology, Nuclear Medicine, Pharmacy, and others. What we need are disease-specific, precise, cost-efficient, and patient-centred care pathways. Expanding integrated diagnostics in this context is a mandatory factor in this equation.

The [EFLM Integrative Diagnostics Committee](#), which operates within the EFLM Science Division is part of the commitment of EFLM to advancing integrative diagnostics and fostering interdisciplinary collaboration. This committee is chaired by Joe Lennerz and includes representatives from a diverse range of specialties, including experts from outside the field of laboratory medicine. Their inclusion ensures a broader perspective and promotes the integration of Laboratory Medicine with other scientific and technological disciplines, further strengthening efforts toward patient-centered diagnostic approaches.

The talk by Prof. Beets-Tan was entitled "**Culture shifts and the impact on integrated diagnostics**" and she provided a phenomenal overview.

Some highlights were the increasing demand for preventative and patient-centred pathways, that AI has the potential to reduce screening cost and she provided 3 perfectly understandable areas of interest (screening, minimally invasive procedures, and precision medicine).

Dynamic response prediction (at baseline, during treatment, and after treatment) was another highlight and she even provided ctDNA as a powerful laboratory toolkit in her excellent talk.

The integration of all biomarkers formed an excellent final slide and the talk was very well received. Her call to action to a packed room was that we must move from segregated diagnostics to integrated diagnostics.



EFLM OFFICE INFORMS

EFLM President, Prof. Mario Plebani, Ranked #1 Among Highly Cited Scholars

Reported by **Silvia Cattaneo**, EFLM Office

As has become a tradition for other EFLM Presidents, the EFLM Office is proud to share with the EFLM community an international recognition awarded to our current President, Prof. Mario Plebani: he has been ranked **#1** in the *ScholarGPS™ Highly Ranked Scholars™* 2024 list as the **most productive author whose works are of profound impact and utmost quality**, based on h-index ranking, in two specialties: "[Medical Laboratory](#)" and "[Clinical Chemistry](#)".

The ScholarGPS™ rankings are based on data reflecting scholars' lifetime or previous five-year academic activity. Each publication and citation is carefully weighted according to the number of contributing authors and self-citations are excluded to ensure the integrity of the evaluation.

This prestigious recognition highlights Prof. Plebani's exceptional scientific achievements and his lasting influence in the field.

Our heartfelt congratulations to Prof. Plebani: we are honoured to have him as EFLM President!

EFLM OFFICE INFORMS

Call for Vacancies: new open positions are available in EFLM Committees!

Reported by **Alessia Carere**, EFLM Office

We are delighted to inform you that two new EFLM functional units have been recently established:

the EFLM Committee "Exchange of Laboratory Data" (C-ExLD)

under the chairmanship of Dr Ruben Smeets (The Netherlands).

The Committee is aimed at supporting efforts to standardize the exchange of laboratory data between laboratories and between countries and ensure that essential information is included in the European standard for data exchange.

We are now calling for nominations for:

- **3 Full Members**
- **1 Young Scientist Member (to be less than 40y of age as of 1st January 2026)**

the EFLM Committee "Laboratory Error Database" (C-LED)

under the chairmanship of Dr Hikmet Can Çubukçu (Türkiye).

The Committee is aimed at developing, implementing, and maintaining a continuously updated database. This resource will cover various laboratory errors, their impact on test results, the severity of harm they can cause, and supporting references.


We are now calling for nominations for:

- **3 Full Members**
- **1 Young Scientist Member (to be less than 40y of age as of 1st January 2026)**

We warmly invite you to visit the dedicated page to obtain detailed information:

<https://www.eflm.eu/site/EFLM-open-positions>

We hope to receive many expressions of interests from EFLM National Societies!



Mark in your agenda the deadline of **30 September** and do not miss the opportunity to actively participate in the EFLM community.

[Click on the link above to know more about the requirements and the evaluation procedure.](#)

The term of office will be for 2 years. The position could be renewable for other two more terms if the work for the Committee is deemed essential at that time. The work is mainly conducted by e-mail and teleconferencing, the Committee usually meets once per year. Procedure for applications: **each National Societies Full Member of EFLM can submit one nomination using the dedicated form** to be sent back to eflm@eflm.eu. A brief plan of the applicant's contribution to the aims and objectives of the relevant Committee must be included in the form. Candidates must be officially recommended by their National Society through a formal letter of support. Applicants who are not selected as full members may be eligible for corresponding membership.

Changing of the Guard in EFLM National Societies

Reported by **Alessia Carere**, EFLM Office

A warm welcome to the new incoming National Society officers and a great thank you to the outgoing EFLM National Representatives and National Society Presidents for the support to EFLM activities during their terms of office.

Association of Laboratory Medicine, UK


We are glad to inform that Ian Godber (Biochemistry Dept., Laboratory Medicine and FM Building, Queen Elizabeth University Hospital, Glasgow, UK) is the new President of the Association of Laboratory Medicine, replacing Katharine Hayden.

Danish Society of Clinical Biochemistry

We are glad to inform that Mie Samson (Dept of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark) is the new President of the Danish Society of Clinical Biochemistry, replacing Mads Nybo.

Call for Participation – EFLM Survey on Alzheimer’s Disease Biomarkers

by **Luisa Agnello**, Member of the EFLM Committee on Harmonisation



The EFLM Committee “Harmonization” is pleased to announce the launch of a new survey focused on Alzheimer’s disease (AD) biomarkers.

AD represents one of the most pressing public health challenges of our time. As populations age, the burden of neurodegenerative diseases continues to rise, making early, accurate, and accessible diagnosis a global priority.

In recent years, laboratory medicine has assumed a pivotal role in transforming the diagnostic landscape of Alzheimer’s disease (AD). Once reliant solely on clinical symptoms and imaging, today’s diagnostic approach increasingly incorporates biomarker-based testing to detect the earliest molecular changes, often decades before the onset of cognitive decline.

Key biomarkers, such as amyloid-beta peptides (A-42, A-40), phosphorylated Tau (pTau), total Tau (tTau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), offer measurable insights into the underlying pathophysiology of AD. Their detection in cerebrospinal fluid (CSF) and, more recently, in blood-based samples is opening new doors for screening, disease staging, and monitoring therapeutic responses.

However, with innovation comes the need for harmonization across laboratories. Variations in pre-analytical handling, analytical methods, cut-off values, and reporting can affect the interpretation and comparability of results.

By standardizing practices and fostering data sharing, the laboratory community plays a crucial role in enhancing diagnostic confidence and accessibility across Europe. The integration of biomarker testing into routine clinical care not only supports early diagnosis but also facilitates research into disease-modifying treatments, bringing us closer to more effective management and, ultimately, prevention of AD. The future of AD diagnosis is closely tied to the advancement of laboratory medicine.

The EFLM Survey on Alzheimer’s disease biomarkers aims to capture a comprehensive overview of current practices across European laboratories, including matrices and biomarker panels currently in use (CSF, blood, or both); pre-analytical protocols, including sample handling and storage; analytical methods and instrumentation used for measurement; reporting standards, use of cut-offs, ratios, and classification frameworks (e.g., ATN); turn-around times and interpretive practices.

With growing clinical reliance on AD biomarkers, it is crucial to understand and harmonize laboratory workflows to improve result comparability and diagnostic confidence.

We kindly ask for your participation to help us identify practice gaps, variability, and harmonization needs across Europe.

[Click here to access the survey](#)

THE SURVEY WILL REMAIN OPEN TILL 15 OCTOBER 2025

EFLMLabX Training experience

Reported by **Irem Açılan**, Türkiye, EFLM bursary recipient

I would like to begin by expressing my heartfelt gratitude to Prof. Enrico Iaccino for warmly welcoming me into his laboratory and for his invaluable guidance throughout my stay. I am also deeply thankful to the EFLM Committee for organizing such a valuable and inspiring program for young scientists and doctors like myself. Lastly, I extend my sincere appreciation to our department head, Prof. Dr. Ali Ünlü, for his continuous support and encouragement, which made this enriching experience possible.

As a resident doctor in the Department of Medical Biochemistry at Selçuk University Hospital in Turkey, I am driven by a passion for advancing my knowledge and skills in the field. This motivation led me to apply for and be accepted into the EFLM LabX program, where I had the incredible opportunity to receive one month of hands-on training in the laboratory of Prof. Enrico Iaccino at the University "Magna Graecia" of Catanzaro, Italy.



During my engaging training, I focused on the fascinating world of extracellular vesicles (EVs)—particularly exosomes—and their pivotal role in the diagnosis and treatment of neurodegenerative disorders like Parkinson's disease (PD) and progressive supranuclear palsy (PSP), as well as hematologic malignancies such as multiple myeloma and leukemias. The complexity of these conditions and the potential for EVs to serve as biomarkers for early detection and monitoring captivated my interest.

One of the most critical challenges in the application of liquid biopsies based on EVs is the pre-analytical variability, which can obscure biomarker detection and compromise diagnostic accuracy. I was inspired by how Prof. Iaccino's laboratory actively tackles these challenges through systematic and innovative approaches designed to minimize pre-analytical errors. This includes emphasizing meticulous sample collection, optimizing factors such as the choice of collection tubes and anticoagulants to prevent degradation or contamination of EVs.

The laboratory adheres to strict protocols for sample management and processing, ensuring minimal delays and maintaining optimal handling conditions to preserve the integrity of EVs. We delved into the importance of standardized storage protocols to safeguard against EV degradation, and refined isolation techniques were utilized to enhance yield and purity while minimizing contamination. The research conducted in the lab also explores how patient-related factors can influence the concentration and composition of circulating EVs. This understanding is crucial for refining the standardization protocols for liquid biopsy procedures, ultimately improving diagnostic outcomes.

Throughout my training, I had the remarkable opportunity to work with advanced instrumentation and techniques that brought theory to life. I engaged in ultracentrifugation for EV isolation, which allowed me to appreciate the intricacies of extracting these tiny yet significant vesicles from biological fluids. Nanoparticle tracking analysis (NTA) enabled me to size and quantify the EVs effectively, while flow cytometry provided a powerful means to characterize EV subpopulations in detail. Additionally, I took part in RNA extraction and analysis, which equipped me with the skills to examine the molecular cargo within EVs, revealing insights into their biological functions and potential roles in disease.

The excitement did not stop there; to further elevate the reliability of liquid biopsies, there is an inspiring push for automation in the purification and characterization of EVs. I was thrilled to learn about the exploration of automated platforms, including microfluidic devices and robotic systems, which promise to reduce human error and ensure consistent sample treatment. The integration of high-throughput technologies, such as automated flow cytometry and single-particle analysis, allows for a comprehensive profiling of EV subpopulations, particularly those derived from neurons (EVn). Understanding these subpopulations is crucial for unlocking their specific roles in neurological health and disease, and I found this aspect of the research particularly captivating, as it holds the potential for groundbreaking advances in diagnostics and therapeutics.

In conclusion, my training in Prof. Iaccino's laboratory has been a truly transformative experience that reinforced the importance of addressing pre-analytical variability in liquid biopsies while highlighting the exciting potential for automation in EV processing. By focusing on these challenges and deepening our understanding of EV biology, especially regarding neuronal-derived EVs, we can unleash the full potential of these groundbreaking diagnostic tools. The knowledge and skills I have gained during this program are invaluable, and I am immensely grateful for this opportunity. I wholeheartedly encourage my colleagues to engage with such inspiring research experiences, as they are essential for our growth as scientists and healthcare professionals. Thank you once again, Prof. Enrico Iaccino and his team, for their warm hospitality, exceptional guidance, and for making this incredible journey an unforgettable one!

EFLMLABX CORNER
LAB 

THE EFLM LABORATORY
EXCHANGE PROGRAMME





EUROPEAN
LABORATORY DAY



NOVEMBER 5TH, 2025



ACROSS EUROPE

SAVE THE DATE



#EULabDay2025
#EFLM



NEWS FROM EFLM FUNCTIONAL UNITS

Four simple actions to be more sustainable and green in your laboratory!

Reported by **Tomris Ozben**, Chair
of the EFLM Committee "Green &
Sustainable Laboratories"


In line with the goal of the [EFLM Committee "Green & Sustainable Laboratories"](#), I have the pleasure to continue the column: Four simple actions to be more sustainable and green in your laboratory!

In each issue of the newsletter, we will select 4 actions from each section of the checklist prepared by the EFLM TF-GSL members (Chemicals, Energy, Waste and Water) to start implementing the daily routine in your laboratories and getting familiar with the checklist.

The below actions are accompanied by a graphical leaflet that you can download and post in the notice board of your laboratory to be shared with your colleagues (in this case, please remember to use recycled paper).

[Click here to download the PDF](#)

FOUR SIMPLE ACTIONS TO BE MORE SUSTAINABLE AND GREEN IN YOUR LABORATORY!



The selected actions of this issue are:

✔ Section "Hazardous Chemicals Management"

ACTION: Are there written Standard Operating Procedures for chemical waste management?

✔ Section "Energy Management"

ACTION: Are your refrigerators and freezers energy efficient/smart?

✔ Section "Waste Management"

ACTION: Do you identify single-use plastics that could be recycled, reused or substituted with other materials such as glass?

✔ Section "Water Management"

ACTION: If you are using autoclaves/sterilizers in your lab, do you share them with other departments?




A message from Cristina Marques, SPML President

Brussels, May 2025 – The official Portuguese (European) translation of the *EFLM Green and Sustainable Clinical Laboratories Guidelines* was formally handed over to the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) at the EFLM booth during EuroMedLab 2025 in Brussels. EFLM was represented by Ms. Silvia Cattaneo. Representing the Sociedade Portuguesa de Medicina Laboratorial (SPML) were Cristina Marques and Lucas Biaggini, acting on behalf of SPML's dedicated workgroup for green and sustainable laboratories. This milestone highlights the ongoing collaboration between National Societies and the EFLM to promote sustainability in Laboratory Medicine across Europe."

You can find all the available translations of the EFLM GSL guidelines on the [Green Labs website](#).



We would be more than happy to receive other official translations of the EFLM GSL guidelines from the EFLM National Societies. For any further information, please contact eflm@eflm.eu



New EFLM publications have been produced by EFLM functional units!

UPDATES ON EFLM PUBLICATIONS

New EFLM scientific papers have been published!

Reported by **Alessia Carere**, EFLM Office

The EFLM Office is happy to announce the latest published EFLM papers, developed by EFLM functional units to share knowledge and promote best practices across Europe and beyond. Discover all EFLM publications at the dedicated page of the EFLM website <https://www.eflm.eu/site/eflm-publications>, where with the retrieval function you can search publications for title, author, keywords or EFLM functional units producing the paper.

Regulating the future of laboratory medicine: European regulatory landscape of AI-driven medical device software in laboratory medicine

Can Çubukçu H, Boursier G, Linko S, Bernabeu-Andreu F. A, Brguljan P. M, Tosheska-Trajkovska K, Brugnoli D, Milinkovic N, Padoan A, Thelen M, on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Division: Quality, Standards and Regulations, Committee on Accreditation and ISO/ CEN standards (C: A/ISO)
[Clin Chem Lab Med 2025](#)

A value-based score for clinical laboratories: promoting the work of the new EFLM committee

Plebani M
[Clin Chem Lab Med 2025](#)

New insights in preanalytical quality

Plebani M, Scott S, Simundic AM, Cornes M, Padoan A, Cadamuro J, Vermeersch P, Can Cubukcu H, Gonzalez A, Nybo M, Salvagno GL, Costelloe SJ, Falbo R, von Meyer A, Iaccino E, Botrè F, Banfi G, Lippi G
[Clin Chem Lab Med 2025](#)



PAST EFLM EVENTS

Past EFLM webinars

Reported by **Aleš Kvasnička**,
Chair of the Committee:
Young Scientists and
Member of the Committee:
Promotion & Publications



The Microbiome and Mediterranean Diet

Speaker: Lihi Godny (Israel)


The webinar delved into how dietary patterns influence gut health. Godny began by reviewing the central role the intestinal microbiome plays in maintaining overall health and in the pathogenesis of gastrointestinal disorders. She then explained how specific nutrients and eating habits modulate microbial composition and function, stressing the bidirectional relationship between diet and microbial metabolites. The session concluded with a focused examination of the Mediterranean diet's impact on patients with inflammatory bowel diseases, highlighting evidence that its fiber-rich, polyphenol-laden foods foster a more diverse, anti-inflammatory microbiome and may contribute to symptom control and disease modulation.



How to ensure correct POCT results? – with focus on solutions

Speaker: Anne Stavelin (Norway)


The webinar explored practical strategies for safeguarding point-of-care testing (POCT) accuracy. Dr. Stavelin first outlined criteria for choosing reliable, user-friendly POCT devices tailored to specific clinical contexts, emphasizing analytical performance, connectivity, and ease of maintenance. She then detailed optimal schedules and methods for ongoing quality assurance-ranging from daily internal checks to periodic external proficiency testing-to rapidly detect and correct deviations. Finally, the session highlighted the pivotal role of structured training, clear procedural guidance, and continuous follow-up of POCT users, demonstrating how education and feedback loops translate technical standards into consistently trustworthy bedside results.



Liquid biopsy - a new era for management of solid tumors

Speaker: Marzia Del Re (Italy)

In this webinar, the attendees learned how liquid biopsy is reshaping oncologic care. Dr. Del Re first appraised the interpretation of liquid-biopsy results, detailing how circulating tumor DNA and other analytes can reveal tumor heterogeneity and real-time molecular evolution. She then demonstrated practical applications across a spectrum of solid tumors-from guiding targeted therapies in lung cancer to monitoring minimal residual disease in colorectal and breast malignancies-underscoring the technique's versatility throughout the treatment continuum. Finally, she compared current analytical platforms, outlining criteria for selecting the most appropriate technology (e.g., digital PCR vs. next-generation sequencing) based on clinical question, required sensitivity, turnaround time, and cost. Together, these discussions highlighted liquid biopsy's growing role as a minimally invasive, dynamic tool for precision oncology.



Dementia with Lewy body, a biological diagnosis is crucial

Speaker: Armand Perret-Liaudet (France)

The webinar provided an in-depth exploration of the pathophysiological basis underlying Lewy body (LB) dementia and emphasized the importance of developing sensitive and specific biological tools for its diagnosis among other neurodegenerative dementias. Dr. Perret-Liaudet explained why current diagnostic methods are insufficient, highlighting the clinical and research challenges that necessitate a reliable LB biomarker. He also reviewed and discussed various approaches and emerging techniques that could become future candidates for accurate LB diagnosis, offering valuable insights into ongoing scientific advancements in the field.

UPCOMING EFLM EVENTS

New insights in preanalytical quality

Join Us for the 7th EFLM Conference on the Preanalytical Phase!

by EFLM Office

We invite you to be part of the **7th EFLM Conference on Preanalytical Phase**, a premier event dedicated to advancing knowledge and best practices in the crucial preanalytical phase of laboratory medicine. The conference will bring together leading experts, researchers, and professionals to share cutting-edge insights and foster meaningful collaboration.

7th EFLM CONFERENCE ON PREANALYTICAL PHASE

New insights in
preanalytical quality

PADOVA

12-13 DECEMBER 2025



A reminder for you to not miss the following deadlines!

As the event approaches, please make note of these key dates to ensure your active participation:

- | | |
|---------------------------|---|
| September 7, 2025 | Abstract Submission Deadline: Share your latest research and innovative practices by submitting an abstract. |
| September 30, 2025 | EFLM Walter Guder Preanalytical Award (sponsored by BD) Deadline: apply for this prestigious award granted to the best published paper demonstrating an important and novel contribution to the advancement of the preanalytical phase. |
| October 3, 2025 | Notification of Acceptance or Rejection: You will receive confirmation regarding the status of your submitted abstract. |
| October 5, 2025 | EFLM Bursary Application Deadline: Apply for financial support to help cover your attendance. |
| October 15, 2025 | Early Registration Deadline: Take advantage of discounted rates by registering early. |

Don't miss this opportunity to engage with fellow experts, gain fresh perspectives, and be part of the vibrant scientific community driving innovation in the preanalytical phase.

We look forward to seeing you there!

EFLM Strategic Conference 2026

Laboratory Medicine for Society

24 – 25 April 2026 Prague, Czech Republic
Vienna House by Wyndham Diplomat Prague

<https://www.eflm-strategic-conference2026.cz>

16–20 May 2027 | Excel London
EUROMEDLAB 2027

27th Congress of Clinical Chemistry and
Laboratory Medicine
LABMEDUK27 of the Association for Laboratory
Medicine

Forthcoming EFLM webinars


Reported by **Aleš Kvasnička**, Chair of the Committee: Young Scientists and Member of the Committee: Promotion & Publications



Risk and patient-based quality control in clinical laboratories

Date: 5 August 2025 at 18:00 CET time

Speaker: Hikmet Can Cubukcu (Turkey)



Anemia: old disease / new laboratory approaches

Date: 16 September 2025 at 18:00 CET time

Speaker: Eloísa Urrechaga (Spain)



Leadership Strategies for Driving Data Analytics in Laboratory Management

Date: 23 September 2025 at 18:00 CET time

Speaker: Sedef Yenice (Turkey)



MEET THE EXPERT

Novel equations for estimating LDL-cholesterol from the standard lipid profile

Date: 25 September 2025 at 16:00 CET time


Speaker: Michel Langlois (Belgium; Marielle Kaplan (Israel)



Cardiovascular biomarkers in a Point-of-care Testing environment

Date: 7 October 2025 at 18:00 CET time

Speaker: Álvaro García Osuna (Spain)




Advanced molecular testing by Nuclear Magnetic Resonance for cardio-metabolic disease diagnostics

Date: 21 October 2025 at 18:00 CET time

Speaker: Núria Amigó Grau (Spain)

Forthcoming EFLM webinars

Reported by **Aleš Kvasnička**, Chair of the Committee: Young Scientists and Member of the Committee: Promotion & Publications



Reference Intervals Based on the Metabolic Activity of Analytes

Date: 4 November 2025 at 18:00 CET time

Speaker: Abdurrahman Coşkun (Turkey)



Plasma pTau-217 as a New Diagnostic Tool for Alzheimer Disease Diagnosis

Date: 18 November 2025 at 18:00 CET time

Speaker: Mireia Tondo Colomer (Spain)



MEET THE EXPERT

Analysis and interpretation of laboratory testing of inherited thrombophilia

Date: 20 November 2025 at 16:00 CET time


Speaker: Christelle Orlando (Belgium); Zsuzsa Bagoly (Hungary)



Analysis of Circulating DNA and Clinical Utility in Cancer: A Perspective from the Clinical Laboratory

Date: 2 December 2025 at 18:00 CET time

Speaker: Angel Díaz-Lagares (Spain)



Clinical use of E2 and TESTO and the significance of their low values, measured by LC-MS

Date: 16 December 2025 at 18:00 CET time

Speaker: Annemieke Heijboer (Netherlands)

All webinars are free for EFLM Academy members.

[Join on EFLM e-learning platform!](#)

NEWS FROM EFLM NATIONAL SOCIETIES

Society of Medical Biochemists of Serbia: 70 Years of existence and work

Reported by **Nada Majkic-Singh**, SMBS National Representative



This year, the Society of Medical Biochemists of Serbia (DMBS) is celebrating the 70th anniversary of its dedicated work. As a member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), the Society has contributed to the advancement of clinical chemistry and laboratory medicine both in Serbia and internationally. The Society is also a member of the regional Balkan Clinical Laboratory Federation (BCLF).

[DOWNLOAD THE FULL REPORT](#)

EFLM Postgraduate Course on Biostatistics in Laboratory Medicine in collaboration with the Society of Medical Biochemists of Serbia

Reported by **Neda Milinković** and **Snežana Jovičić**

From July 1 to 3, 2025, the Society of Medical Biochemists of Serbia hosted the Advanced Postgraduate Course in Biostatistics, led by Professor Matteo Vidali from Italy. The course was organized under the auspices of the European Federation for Laboratory Medicine (EFLM) and was organized in Belgrade, at the Faculty of Pharmacy-University of Belgrade. This was the first time Prof. Vidali delivered an intensive, three-day advanced biostatistics program focused on the use of the R statistical software.

The course comprised eight hours of instruction per day, combining theoretical lectures with practical, hands-on sessions. Each participant had R installed on their personal computer, and Prof. Vidali provided comprehensive guidance on both the fundamentals of the R programming language and its application in statistical analysis. The curriculum covered a wide range of topics, including descriptive statistics, inferential statistical tests, correlation and regression analysis, diagnostic accuracy, outlier detection, and method comparison.


To facilitate practical learning, Prof. Vidali supplied curated datasets for daily exercises, allowing participants to apply theoretical knowledge to real-world laboratory and clinical scenarios. The course also introduced participants to the method comparison protocol currently used in Italy, along with proprietary software

developed and patented by Prof. Vidali for evaluating method comparison in laboratory settings.

A total of 32 participants attended the course, representing diverse backgrounds in basic, translational, and clinical research. Attendees included PhD students and holders, university professors, and MSc graduates in pharmacy and medical biochemistry.

At the conclusion of the course, participants completed an evaluation survey. Feedback indicated that the course was well-structured, clearly presented, and highly beneficial. Participants appreciated the detailed course materials, which were provided as a gift, and praised Prof. Vidali for his expertise and enthusiasm. While some suggested extending the course duration, the majority agreed that the three-day format provided a solid foundation in advanced biostatistics. Professor Vidali emphasized the importance of continued practice to achieve proficiency in R programming.

This course represents a significant contribution to the continuing education of researchers and healthcare professionals in the region, enhancing their capacity for data analysis and evidence-based decision-making. Society of Medical Biochemists of Serbia and participants extend their sincere gratitude to Professor Matteo Vidali for his outstanding contribution, dedication, and inspiring teaching throughout the course.



First joined Satellite Symposium between the SFBC and the RBSLM

"Preventive Diagnostics: The Power of Laboratory Medicine"

Reported by **Katell Peoc'h**¹, and **Etienne Cavalier**²

¹SFBC, Université Paris Cité, APHP, Paris, France,

²RBSLM, University of Liège, CHU of Liège, Liège, Belgium

On May 18th, 2025, beneath the futuristic arches of Brussels' Atomium, the French Society of Clinical Chemistry (SFBC) and the Royal Belgian Society of Laboratory Medicine (RBSLM) co-hosted the first common Satellite Symposium. This event aimed to position laboratory medicine at the very heart of tomorrow's preventive healthcare. As part of the EuroMedLab 2025 conference, the event brought together scientists, clinicians, and policy experts around a compelling theme: "Preventive Diagnostics: The Power of Laboratory Medicine." The idea for this first joint symposium initially germinated in the spirit of the boards of the SFBC and RBSLM, relayed by the Presidents. V. Sapin and D. Gruson, a few months ago.

The symposium served as an academic gathering and a strategic reflection on how diagnostics can shift healthcare from reactive intervention to anticipatory action. Through a full day of scientific dialogue and brainstorming, participants explored how biomarkers, personalized approaches, and integrated testing platforms are reshaping the way we detect, monitor, and ultimately prevent disease.

Chaired by Dr E. Lebretonchel and Pr. P. Vermeersch, the morning began with a deep dive into Lipoprotein(a) [Lp(a)], an often overlooked but increasingly recognized marker in cardiovascular health. Pr. M. Langlois explained how elevated Lp(a) levels—especially in genetically predisposed individuals—constitute a major independent risk factor for atherosclerotic cardiovascular disease. Despite its clinical relevance, Lp(a) remains underutilized due to assay variability and lack of awareness. Pr. Langlois called for standardized measurement protocols and proposed integrating Lp(a) into cardiovascular screening programs, particularly for patients with familial hypercholesterolemia or unexplained premature coronary events.

The focus then shifted to neurodegenerative diseases, with Prof S. Lehmann and J.L. Bayart emphasizing the potential of plasma neurofilament light chain (NfL) and beta-amyloid concentrations as early indicators of neurodegeneration. Their analysis illustrated how these biomarkers can detect subtle changes years before clinical symptoms arise in conditions such as Alzheimer's and Parkinson's disease. Integrating such laboratory analysis into routine screenings, they argued, could enable preclinical interventions and pave the way for more effective disease-modifying therapies.

Prof. M. Plebani followed with a macroeconomic and strategic perspective, presenting a case for preventive diagnostics as a lever for cost containment. Through comparative models, he demonstrated how early laboratory testing—especially in chronic conditions such as diabetes, cardiovascular disease, and cancer—can reduce downstream costs linked to hospitalization and advanced interventions. He advocated for outcome-driven funding models, where laboratories are rewarded for contributing to long-term health outcomes, rather than just episodic diagnoses.

Rounding off the morning, Prof. E. Cavalier presented the European interpretation of the 2024 KDIGO guidelines for chronic kidney disease (CKD). The European interpretation is the first step of personalized medicine. He emphasized the importance of increased awareness and consistent use of key markers, such as the estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio. These tests, he argued, should form the backbone of a risk-based screening framework to identify CKD at early, modifiable stages—before irreversible damage occurs. In the afternoon, the symposium, chaired by Prs. V. Sapin and E. Cavalier shifted to the applied, cross-disciplinary aspects of preventive diagnostics.

The session opened with Dr. G. Grzych and Dr. K. Anseeuw tackling the growing public health challenge of nitrous oxide (N₂O) abuse, particularly among young adults. They proposed a collaborative framework. They showed how the association of non-specific clinical signs, and markers—notably vitamin B12 concentrations and methylmalonic acid—may enable timely diagnosis and prevent irreversible neurological complications. Their presentation called for harmonized data sharing and public health vigilance.

Pr. M. Hermans then explored residual cardiovascular risk in diabetic patients, noting that many individuals remain at high risk despite controlled blood glucose concentrations. He introduced a refined risk model that incorporates advanced lipid testing (e.g., apolipoproteins, lipoprotein subfractions), inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP), and renal function indicators, allowing for more precise stratification and personalized treatment plans.

The field of oncology was then addressed by Pr. R. Van Schaik, who made a compelling case for integrating pharmacogenetics

into cancer therapy. Using case studies, he illustrated how genetic variations in enzymes such as DPYD and TPMT can affect the metabolism of chemotherapeutic drugs, including fluoropyrimidines and thiopurines. Identifying these variants in advance enables clinicians to tailor doses, minimize toxicity, and avoid potentially life-threatening reactions, thus making pharmacogenetics a tool for safety and a pillar of preventive oncology.

Finally, Dr. C. Gobeaux offered a future-oriented view on cardiovascular prevention, exploring the promise of high-sensitivity troponins, genetic risk scores, and integrated digital tools for risk stratification in asymptomatic individuals. Her presentation advocated a seamless interface between laboratory data and digital health ecosystems, enabling long-

term, proactive cardiovascular monitoring.

The symposium concluded with closing remarks from Dr. M. Oyaert and Pr. K. Peoc'h, who reaffirmed the central message of the day: that the laboratory is not a passive recipient of clinical demand but an active driver of anticipatory and predictive medicine. They called for greater investment in research, interdisciplinary collaboration, and the integration of laboratory data with clinical decision-making. Indeed, we all believe that the Lab saves lives.


In sum, the event shed new light on laboratory medicine, not only as a science of precision but also as a discipline of foresight. With its capacity to detect the silent signals of disease, laboratory diagnostics can transform healthcare from a system that reacts to illness into one that anticipates and prevents it.



In the Atomium, looking out over Brussels.



Prof. Michel Langlois, presenting the history of Lp (a)



Prof. Mario Plebani, presenting value-based laboratory medicine concepts



Prof. Etienne Cavalier pinpointed the need for a European interpretation of the KDIGO recommendations's



Concluding remarks from Dr. M. Oyaert and Pr. K. Peoc'h

Experts emphasize the importance of a multidisciplinary approach to liver disease at the 2nd Conference on Innovation in Laboratory Medicine (iMedLab)



- 30% of the Spanish population suffers from metabolic fatty liver disease, one of the most common liver diseases.
- Clinical laboratory specialists play a key role in the diagnosis and monitoring of liver disease and transplantation, as they are responsible for the laboratory tests on which clinical decisions are based.
- Raising awareness about liver health, educating the population, promoting healthy lifestyle habits, and ensuring multidisciplinary treatment are fundamental factors in the prevention and control of liver damage.
- The use of artificial intelligence and omics technologies in the laboratory will improve the accuracy of diagnosis and prognosis.

The liver is an organ that acts as the silent guardian of internal balance and overall well-being. Its function is key to digestion, metabolism, blood clotting, and the elimination of toxic substances. A failure in its activity can lead to serious health problems and the development of diseases, from cirrhosis to liver cancer, which can seriously compromise not only the life and survival of patients, but also the physical, emotional, and social well-being of those who suffer from them.

In this context, the **Spanish Society of Laboratory Medicine (SEMEDLAB)** presented its scientific event, the **2nd Conference on Innovation in Laboratory Medicine (iMedLab): "The Challenge of Liver Disease"**. Understanding and Working as a Team to Find Solutions." On April 7 and 8, experts in Laboratory Medicine and other disciplines gathered to present and discuss the latest developments in pathology, diagnosis, and treatment, as well as the most notable advances in research projects. The patient perspective and the impact of these diseases on their quality of life were also taken into account.

Generally speaking, a significant percentage of Spaniards do not have a healthy liver. Approximately 30% of the population suffers from metabolic fatty liver disease (MFD), according to population studies. MFD is one of the most common liver diseases, closely linked to risk factors such as a sedentary lifestyle and diseases like obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease. This was stated by Dr. Raquel Gómez Molina, a member of the SEMEDLAB Communications Committee, who noted that these same factors also contribute to the development of other liver diseases, such as non-alcoholic fatty liver disease and advanced fibrosis, "which demonstrates the influence of lifestyle habits on the development of liver disease."

Alcohol and Liver Disease

In Spain, as Dr. Gómez Molina noted, alcohol consumption remains a "deeply rooted" habit in many regions, increasing the risk of

developing liver diseases such as cirrhosis and fatty liver disease. Furthermore, the prevalence of obesity and overweight status has increased considerably in recent decades, "which favors the development of non-alcoholic liver diseases, especially among adults of lower socioeconomic status."

An additional problem, as Dr. Gómez Molina pointed out, is that many liver diseases are asymptomatic in their early stages, which delays diagnosis and treatment. In this regard, there is a stigma associated with liver disease due to its association with alcohol consumption in Spanish society. This perception, as the expert stated, "can cause patients to delay seeking medical attention out of shame or fear of social judgment, which complicates early diagnosis and appropriate treatment." Therefore, Dr. Gómez Molina emphasized the importance of adopting healthy habits to prevent and avoid liver damage, without forgetting the need for a comprehensive and multidisciplinary approach. Thus, addressing liver disease requires the intervention of the Emergency Department, Primary Care, and Psychological Care departments, along with digestive specialists and nursing staff, "who play a fundamental role in patient education and follow-up." In this situation, the Clinical Laboratory physician plays a key role, both in the detection and monitoring of these types of liver diseases. As stated by Dr. María del Monte Jarabo, a physician from the Clinical Laboratory Service at GAI La Mancha Centro, "they are the specialists responsible for the laboratory tests on which the clinicians base their decisions to establish the diagnosis. Follow-up is also based on the progression of the laboratory tests, as well as clinical improvement." Liver function laboratory tests cover a wide range of diseases, but, as Dr. Jarabo points out, a first step in detecting liver disease is the determination of liver enzymes. Additionally, depending on the patient's symptoms and suspicion, more specific tests may be ordered, such as serology for infectious hepatitis, autoantibodies for autoimmune diseases, etc. Along these lines, clinical laboratory tests are essential for the approach to liver transplantation, as it is a complex medical intervention

that involves a series of procedures and critical decisions at each stage, from donor evaluation to postoperative management. Thus, as the experts participating in the conference emphasized, during this process, “the clinical laboratory plays a crucial role by providing accurate diagnostic information through liver function tests, microbiological analyses, and immunological compatibility studies, which allows us to determine the status of the graft and reduce the risk of complications after the operation.”

Immunotherapy in Liver Cancer

The development of immunotherapy treatments for liver cancer has been one of the most notable innovations in the approach to liver disease. This was noted by Dr. Matilde Bustos de Abajo, a researcher with the Spanish National Research Council (CSIC) at the Institute of Biomedicine of Seville (IBiS), who also highlighted “the treatments and medications for non-alcoholic fatty liver disease or fatty liver disease associated with metabolic dysfunction.” Furthermore, in hepatitis C, “direct-acting antivirals have achieved high cure rates with fewer side effects than previous treatments,” stated Dr. Bustos de Abajo. In the coming years, the search for

diagnostic and prognostic biomarkers of chronic liver disease for the early detection of liver cancer is expected to be a promising line of research. In the field of Laboratory Medicine, as Dr. Bustos de Abajo commented, the discipline will advance toward “advanced diagnostic tests that can detect and assess liver damage and fibrosis in early stages, as well as the discovery of noninvasive biomarkers to evaluate steatosis, fibrosis, and inflammation.” It is also worth noting that omics technologies will enable advances in personalized medicine and predict the progression of liver disease. Furthermore, Dr. Jarabo emphasized that advances in computer science and artificial intelligence will allow “optimizing the extraction of information from the large amount of data generated by the laboratory in conjunction with clinical data.” In this area, and as a closing presentation, the speakers introduced the foundations of machine learning techniques, as well as the generation and learning process of the different machine learning models. Furthermore, some of the articles published by the experts in high-impact journals were described, in order to demonstrate the practical usefulness of these techniques in evaluating different mortality predictors in the diagnosis of hepatocarcinoma.

NEWS FROM EVENTS UNDER EFLM AUSPICES

43rd Vicenza Course AKI - CRRT - EBPT and Critical Care Nephrology

Reported by **the Organizing Secretariat**, NPS Events

The 43rd Vicenza Course on AKI, CRRT, EBPT and Critical Care Nephrology, held from 24th to 26th June 2025 in Vicenza, Italy, has been a resounding success. Organised by New Progress Service S.R.L., the event once again confirmed its reputation as a leading international forum for scientific exchange and professional networking in the field of nephrology and critical care.

The course gathered 432 delegates from 39 regions worldwide, demonstrating its global appeal and relevance. The scientific content was of the highest calibre, with renowned experts presenting the latest research, clinical practices and technological advances in acute kidney injury, renal replacement therapies and extracorporeal blood purification techniques.

Equally valuable was the opportunity for delegates to connect with peers, fostering collaboration and the exchange of ideas within the international nephrology community. The city of Vicenza provided the perfect setting for this important scientific meeting, combining historical charm with an atmosphere conducive to professional dialogue.

Further information can be found at www.irriv.com and www.npsevents.it. We thank all participants, faculty members, and supporters for their contribution to making this edition of the Vicenza Course a remarkable success.





Dear Colleagues, Dear Friends,

It was truly a pleasure to see so many of you at the **XXVI EuroMedLab 2025** this May in the beautiful city of Brussels. Following the great success of the congress, I'm also delighted to share that we achieved a record-breaking of 9,004 participants and welcomed 115 exhibiting companies. A total of 114 countries were represented, with the highest number of registrations coming from Spain.

These outstanding results reflect the growing global interest in IFCC activities and the EuroMedLab Congress itself. During the congress in Brussels, a rich and diverse scientific programme brought together leading experts from around the world to explore the future of laboratory medicine. Through high-level plenary lectures, symposia, educational workshops, and round table sessions, participants engaged in in-depth discussions on the most pressing topics in the field, including innovations in clinical chemistry, advances in molecular diagnostics, digital pathology, the integration of artificial intelligence in laboratory workflows, and the role of laboratory medicine in personalized healthcare.

These sessions not only highlighted cutting-edge scientific developments and emerging trends but also provided valuable networking opportunities and a platform for open dialogue. The success of the scientific program highlights the strength of the collaboration between IFCC and its industry partners, a partnership that continues to play a crucial role in advancing innovation and progress in laboratory medicine.

This year's congress also introduced several new features: simultaneous translation from English to Spanish was provided, enhancing accessibility for a broader audience. Additionally, all sessions were recorded, a step forward in making the congress more accessible, inclusive, and impactful than ever before.

This year also marked the 4th edition of the IFCC **Young Scientists Forum**. IFCC provided 52 scholarship grants, enabling young scientists from diverse regions to attend and actively participate in the FORUM and EuroMedLab congress. This initiative demonstrates IFCC's strong commitment to supporting and nurturing the next generation of leaders in laboratory medicine.

I would like to remind you about the WorldLab 2026: the 27th International Congress of Clinical Chemistry and Laboratory Medicine. This prestigious event — a joint initiative of the IFCC and the Asia and Pacific Federation of Clinical Chemistry (APFCB) — will be hosted by the Association of Clinical Biochemists of India (ACBI) in New Delhi, in conjunction with the 52nd Congress of the ACBI. We warmly encourage you to attend and participate in this global celebration of laboratory medicine.

It is my pleasure to announce the upcoming EuroMedLab Congress, which will be held in London in 2027.

Thank you once again for your dedication and valuable contributions to the IFCC community.

Wishing you all a restful and enjoyable summer holiday.

With my warmest regards,

Prof. Dr. Tomris Ozben
IFCC President

The time is now to submit your UNIVANTS Application for 2026 recognition

The [UNIVANTS of Healthcare Excellent award program](#) is now accepting applications for the 2026 awards. If you and/or your integrated team are achieving measurable better healthcare outcomes, now is the time to apply. Applications for 2026 recognition will be accepted today (Aug 1st) through until Nov 15th. To submit your free application and/or learn more about the award program, please visit www.UnivantsHCE.com.

Calendar of EFLM events and events under EFLM auspices

Do not miss the opportunity to have your event listed here.

Apply for EFLM auspices!

For more information visit [here](https://www.eflm.eu) or email eflm@eflm.eu



- **EFLM Webinar**
Risk and patient-based quality control in clinical laboratories
on-line, 5 August 2025
- **EFLM Webinar**
Anemia: old disease / new laboratory approaches
on-line, 18 September 2025
- **XVII National Congress Czech Society of Clinical Biochemistry**
Mikulov (CZ), 21-23 September 2025
- **EFLM Webinar**
Leadership Strategies for Driving Data Analytics in Laboratory Management
on-line, 23 September 2025
- **EFLM Meet the Expert - Interpretation of Laboratory results**
Novel equations for estimating LDL-cholesterol from the standard lipid profile
on-line, 25 September 2025
- **Current issues of clinical laboratory diagnostics in Ukraine – 2025**
Kyiv (UA), 2 October 2025
- **EFLM Webinar**
Cardiovascular biomarkers in a Point-of-care Testing environment
on-line, 7 October 2025
- **V Meeting on External Quality Assurance Programs**
on-line, 8 October 2025
- **32nd Meeting of the Balkan Clinical Laboratory Federation, 16th National Conference of the Romanian Association of Laboratory Medicine**
Sinaia (RO), 8-11 October 2025
- **EQALM Symposium 2025**
Leiden (NL), 15-17 October 2025
- **EFLM Webinar**
Advanced molecular testing by Nuclear Magnetic Resonance for cardio-metabolic disease diagnostics
on-line, 21 October 2025
- **3rd congress of the Association of Medical Biochemists in Bosnia and Herzegovina with International Participation**
Banja Luka (BA), 23-26 October 2025
- **23rd National Congress of Clinical Chemistry**
Thessaloniki (GR), 30 October - 1 November
- **EFLM Webinar**
Reference Intervals Based on the Metabolic Activity of Analytes
on-line, 4 November 2025
- **8th ESPT Congress**
Rotterdam, 5-8 November 2025
- **Annual Meeting of the RBSLM 2025**
Brussels (BE), 13-14 November 2025
- **47th Annual Conference of the Association of Clinical Biochemists in Ireland (ACBI)**
Athlone (IE), 14-15 November 2025
- **EFLM Webinar**
Plasma pTau-217 as a New Diagnostic Tool for Alzheimer Disease Diagnosis
on-line, 18 November 2025

Calendar of EFLM events and events under EFLM auspices

Do not miss the opportunity to have your event listed here.

Apply for EFLM auspices!

For more information visit [here](#) or email eflm@eflm.eu



- **EFLM Meet the Expert - Interpretation of Laboratory results**
Analysis and interpretation of laboratory testing of inherited thrombophilia
on-line, 20 November 2025
- **10th International Conference on Quality of Medical Laboratories**
Ljubljana (SI), 25 November 2025
- **The Value of Laboratory Medicine for Athletes and for Sport Physicians**
Milan (IT), 28 November 2025
- **EFLM Webinar**
Analysis of Circulating DNA and Clinical Utility in Cancer: A Perspective from the Clinical Laboratory
on-line, 2 December 2025
- **7th EFLM Conference on Preanalytical Phase**
Improving preanalytical phase through innovation and sustainable solutions
Padova, 12-13 December 2025
- **EFLM Webinar**
Clinical use of E2 and TESTO and the significance of their low values, measured by LC-MS
on-line, 16 December 2025
- **Labquality Days – International Congress on Quality in Laboratory Medicine and Health Technology 2026**
Helsinki (FI), 5-6 February 2026
- **The 10+2 Santorini Conference**
Systems Medicine and Personalised Health and Therapy - The Odyssey from hope to practice: Patient first-Keep Ithaka always in your mind
Santorini (GR), 26-29 March 2026
- **NOxForum**
Lille (FR), 30-31 March 2026
- **Laboratory Medicine for Society**
EFLM Strategic Conference 2026
Prague (CZ), 24-25 April 2026
- **EuroMedLab 2027**
27th European Congress of Clinical Chemistry and Laboratory Medicine
LABMEDUK27 of the Association for Laboratory Medicine
London (UK) 16-20 May 2027

